Marulanda GA, Henderson ER, Johnson DA, Letson GD, Cheong D. Orthopedic surgery options for the treatment of primary osteosarcoma. Cancer Control. 2008 Jan. 15 (1):13-20. [QxMD MEDLINE Link]. [Full Text].
Vander Griend RA. Osteosarcoma and its variants. Orthop Clin North Am. 1996 Jul. 27 (3):575-81. [QxMD MEDLINE Link].
Gorlick R, Janeway K, Marina N. Osteosarcoma. Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 7th ed. Philadelphia: Wolters Kluwer; 2016. 876-97.
Arceci RJ, Weinstein HJ. Neoplasia. MacDonald MG, Seshia MMK, eds. Avery's Neonatology: Pathophysiology and Management of the Newborn. 7th ed. Philadelphia: Wolters Kluwer; 2016. 1048-60.
Weis LD. Common malignant bone tumors: osteosarcoma. Simon MA, Springfield D, eds. Surgery for Bone and Soft-Tissue Tumors. Philadelphia: Lippincott-Raven; 1998. 265-74.
Kim SY, Helman LJ. Strategies to explore new approaches in the investigation and treatment of osteosarcoma. Cancer Treat Res. 2009. 152:517-28. [QxMD MEDLINE Link].
Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008 Mar. 134 (3):281-97. [QxMD MEDLINE Link].
Pochanugool L, Subhadharaphandou T, Dhanachai M, et al. Prognostic factors among 130 patients with osteosarcoma. Clin Orthop Relat Res. 1997 Dec. 345:206-14. [QxMD MEDLINE Link].
Tsuchiya H, Tomita K. Prognosis of osteosarcoma treated by limb-salvage surgery: the ten-year intergroup study in Japan. Jpn J Clin Oncol. 1992 Oct. 22 (5):347-53. [QxMD MEDLINE Link].
Taylor WF, Ivins JC, Unni KK, Beabout JW, Golenzer HJ, Black LE. Prognostic variables in osteosarcoma: a multi-institutional study. J Natl Cancer Inst. 1989 Jan 4. 81 (1):21-30. [QxMD MEDLINE Link].
Hudson M, Jaffe MR, Jaffe N, Ayala A, Raymond AK, Carrasco H, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990 Dec. 8 (12):1988-97. [QxMD MEDLINE Link].
Meyer WH, Schell MJ, Kumar AP, Rao BN, Green AA, Champion J, et al. Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival. Cancer. 1987 Jan 15. 59 (2):374-9. [QxMD MEDLINE Link].
Yang J, Yang D, Cogdell D, Du X, Li H, Pang Y, et al. APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival. Technol Cancer Res Treat. 2010 Apr. 9 (2):161-9. [QxMD MEDLINE Link].
Kubista B, Klinglmueller F, Bilban M, Pfeiffer M, Lass R, Giurea A, et al. Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma. Int Orthop. 2011 Mar. 35 (3):401-11. [QxMD MEDLINE Link].
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009 Apr 1. 115 (7):1531-43. [QxMD MEDLINE Link].
Punzalan M, Hyden G. The role of physical therapy and occupational therapy in the rehabilitation of pediatric and adolescent patients with osteosarcoma. Cancer Treat Res. 2010. 152:367-84. [QxMD MEDLINE Link].
Song WS, Kong CB, Jeon DG, Cho WH, Kim MS, Lee JA, et al. Prognosis of extremity osteosarcoma in patients aged 40-60 years: a cohort/case controlled study at a single institute. Eur J Surg Oncol. 2010 May. 36 (5):483-8. [QxMD MEDLINE Link].
Bu J, Li H, Liu LH, Ouyang YR, Guo HB, Li XY, et al. P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis. Int J Clin Exp Pathol. 2014. 7 (9):6091-6. [QxMD MEDLINE Link]. [Full Text].
Ma W, Zhang X, Chai J, Chen P, Ren P, Gong M. Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma. Tumour Biol. 2014 Dec. 35 (12):12467-72. [QxMD MEDLINE Link].
Zhao W, Xu H. High expression of TRPM8 predicts poor prognosis in patients with osteosarcoma. Oncol Lett. 2016 Aug. 12 (2):1373-1379. [QxMD MEDLINE Link].
Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, et al. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients. J Surg Oncol. 2008 Apr 1. 97 (5):456-61. [QxMD MEDLINE Link].
Peltier LF. Tumors of bone and soft tissues. Orthopedics: A History and Iconography. San Francisco: Norman Publishing; 1993. 264-91.
Kubo T, Furuta T, Johan MP, Adachi N, Ochi M. Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis. Skeletal Radiol. 2016 Sep. 45 (9):1235-42. [QxMD MEDLINE Link].
Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980 Nov-Dec. 153:106-20. [QxMD MEDLINE Link].
Enneking WF, Spanier SS, Goodman MA. Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am. 1980 Sep. 62 (6):1027-30. [QxMD MEDLINE Link]. [Full Text].
Boriani S, Weinstein JN, Biagini R. Primary bone tumors of the spine. Terminology and surgical staging. Spine (Phila Pa 1976). 1997 May 1. 22 (9):1036-44. [QxMD MEDLINE Link].
Hart RA, Boriani S, Biagini R, Currier B, Weinstein JN. A system for surgical staging and management of spine tumors. A clinical outcome study of giant cell tumors of the spine. Spine (Phila Pa 1976). 1997 Aug 1. 22 (15):1773-82; discussion 1783. [QxMD MEDLINE Link].
Winkelmann WW. Rotationplasty. Orthop Clin North Am. 1996 Jul. 27 (3):503-23. [QxMD MEDLINE Link].
[Guideline] NCCN Clinical Practice Guidelines in Oncology. Bone cancer. Version 2.2022. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/bone.pdf. October 8, 2021; Accessed: May 23, 2022.
[Guideline] Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021 Dec. 32 (12):1520-1536. [QxMD MEDLINE Link]. [Full Text].
Ottaviani G, Robert RS, Huh WW, Jaffe N. Functional, psychosocial and professional outcomes in long-term survivors of lower-extremity osteosarcomas: amputation versus limb salvage. Cancer Treat Res. 2010. 152:421-36. [QxMD MEDLINE Link].
Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010 Jul. 11 (7):670-8. [QxMD MEDLINE Link].
Blattmann C, Oertel S, Schulz-Ertner D, Rieken S, Haufe S, Ewerbeck V, et al. Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer. 2010 Mar 12. 10:96. [QxMD MEDLINE Link]. [Full Text].
Vos HI, Coenen MJ, Guchelaar HJ, Te Loo DM. The role of pharmacogenetics in the treatment of osteosarcoma. Drug Discov Today. 2016 Nov. 21 (11):1775-1786. [QxMD MEDLINE Link].
Yang JZ, Ma SR, Rong XL, Zhu MJ, Ji QY, Meng LJ, et al. Characterization of multidrug‑resistant osteosarcoma sublines and the molecular mechanisms of resistance. Mol Med Rep. 2016 Oct. 14 (4):3269-76. [QxMD MEDLINE Link].
[Guideline] Blay JY, Palmerini E, Bollard J, Aguiar S, Angel M, Araya B, et al. SELNET clinical practice guidelines for bone sarcoma. Crit Rev Oncol Hematol. 2022 Apr 21. 174:103685. [QxMD MEDLINE Link]. [Full Text].
Xiao X, Wang W, Wang Z. The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma. Paediatr Drugs. 2014 Dec. 16 (6):503-12. [QxMD MEDLINE Link].
Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct. 17 (10):1396-1408. [QxMD MEDLINE Link]. [Full Text].
Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg Am. 1982 Oct. 64 (8):1121-7. [QxMD MEDLINE Link]. [Full Text].
Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am. 1996 May. 78 (5):656-63. [QxMD MEDLINE Link].
CRAIG FS. Vertebral-body biopsy. J Bone Joint Surg Am. 1956 Jan. 38-A (1):93-102. [QxMD MEDLINE Link]. [Full Text].

Media Gallery

Chest radiograph of patient with osteosarcoma who died from pulmonary metastatic disease. Note the presence of a pneumothorax as well as radiodense (bone-forming) metastatic lesions.
Clinical appearance of a teenager who presented with osteosarcoma of the proximal humerus (same patient as in the following images). Note the impressive swelling throughout the deltoid region, as well as the disuse atrophy of the pectoral musculature.
Radiographic appearance (plain radiograph) of a proximal humeral osteosarcoma (same patient as previous image). Note the radiodense matrix of the intramedullary portion of the lesion, as well as the soft-tissue extension and aggressive periosteal reaction.
Intense radionuclide uptake of the proximal humerus is noted on a bone scan (same patient as previous 2 images).
A comparison bone scan of the involved shoulder (right image) with the uninvolved shoulder (left image) (same patient as previous 3 images).
Magnetic resonance image appearance (T1-weighted image) of osteosarcoma of the proximal humerus (same patient as previous 4 images). Note the dramatic tumor extension into the adjacent soft-tissue regions.
Core needle biopsy instruments commonly used for bony specimens. Craig needle set.
Close-up view of Craig needle biopsy instruments. Cutting cannula with T-handle attached (top) and sheath through which the cutting cannula passes (bottom).
Resected specimen of a proximal tibia osteosarcoma. The primary lesion was such that the knee joint was resected with the primary lesion. Note that the previous longitudinal biopsy tract was completely excised with the specimen.
Intraoperative consultation with the pathologist, in which the surgeon and pathologist view the microscopic appearance of the biopsy specimen.
Intraoperative consultation with the pathologist. A frozen section of the biopsy specimen is being performed.
Intraoperative photograph of a Van Ness rotationplasty procedure. Osteosynthesis of the tibia to the residual femur is being performed. Courtesy of Alvin H. Crawford MD, FACS.
Clinical photograph taken at the conclusion of a Van Ness rotationplasty procedure (same patient as previous image). Note that the new "knee" of the operative side (left side) is purposely reconstructed distal to the normal right knee. This is in anticipation of the future growth potential of the unoperated limb. Courtesy of Alvin H. Crawford MD, FACS.

of 13

Author

Charles T Mehlman, DO, MPH Professor of Pediatrics and Pediatric Orthopedic Surgery, Division of Pediatric Orthopedic Surgery, Director, Musculoskeletal Outcomes Research, Cincinnati Children's Hospital Medical Center

Charles T Mehlman, DO, MPH is a member of the following medical societies: American Academy of Pediatrics, American Fracture Association, Scoliosis Research Society, Pediatric Orthopaedic Society of North America, American Medical Association, American Orthopaedic Foot and Ankle Society, American Osteopathic Association, Arthroscopy Association of North America, North American Spine Society, Ohio State Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Timothy P Cripe, MD, PhD, FAAP Chief, Division of Hematology/Oncology/BMT, Gordon Teter Endowed Chair in Pediatric Cancer, Nationwide Children's Hospital; Professor of Pediatrics, Ohio State University College of Medicine

Timothy P Cripe, MD, PhD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American Association for Cancer Research, American Pediatric Society, American Society of Gene and Cell Therapy, American Society of Pediatric Hematology/Oncology, Connective Tissue Oncology Society, Society for Pediatric Research, Children's Oncology Group

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Omohodion (Odion) Binitie, MD Medical Director, Assistant Member, Department of Sarcoma, Section Head, Orthopedics, Adolescent/Young Adult and Pediatric Orthopedic Oncology, Medical Director, Physical Therapy, Speech Therapy, and Rehabilitation Services, Assistant Fellowship Program Director, Musculoskeletal Oncology, Moffitt Cancer Center; Assistant Professor, Department of Oncologic Sciences, Department of Ortho and Sports Medicine, University of South Florida Morsani College of Medicine

Omohodion (Odion) Binitie, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, Children's Oncology Group, Florida Orthopaedic Society, Musculoskeletal Tumor Society

Disclosure: Nothing to disclose.

Osteosarcoma Questions & Answers

References

Tables

Contributor Information and Disclosures

What would you like to print?